

# News Releases

All Years

Search

Go

[Advanced Search](#)

**MAR 12, 2021**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist**

**FEB 1, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**JAN 13, 2021**

**Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients**

**JAN 5, 2021**

**Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist**

**NOV 13, 2020**

**Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford**

Show  per page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=5&o=60>